Jan 10, 2024 / 12:30AM GMT
Anupam Rama JPMorgan Chase&Co.-Analyst
Yes already, um, welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined my squad, Malcolm, Kunal, [Ray Hall] Priyanka Grover, our next presenting company is Cogent Biosciences. And presenting on behalf of the company, we have CEO, Andy Robbins.
Andy Robbins Cogent Biosciences - Inc. - President & CEO
Great. Thanks, Anupam, for inviting us to the meeting. It's great to be here, and I'm looking forward to the presentations and Q&A today. So before I dive in just sort of remind folks that I'll probably be making some forward-looking statements today, and I would point you to our recent SEC filings for a more thorough assessment of risk associated with the company.
So I encourage you to review those. I'm going to start in use today is kind of a jumping off your beginning recap and sort of level setting for the company and especially your lead asset. So Cogent is a precision
Cogent Biosciences Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
